VCL-CT02

**VCL-CT02** is an investigational trivalent plasmid DNA vaccine developed by Vical for prevention of human cytomegalovirus infection. The vaccine contains three codon-optimized plasmid DNA constructs in phosphate-buffered saline that encode the human cytomegalovirus antigens pp65, glycoprotein B, and immediate-early protein 1, derived from the AD169 strain. Following administration, host-cell expression of these viral antigens is intended to induce CMV-specific cellular and humoral immune responses. VCL-CT02 was evaluated in Phase 1 studies in healthy CMV-seronegative adults by intramuscular and intradermal administration, including studies in which it primed subjects before challenge with the live-attenuated Towne CMV vaccine. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00373412))

Other names

VCL CT02 pDNA vaccinetrivalent pDNA CMV vaccine